Published in J Med Chem on July 27, 2006
4-N-, 4-S-, and 4-O-chloroquine analogues: influence of side chain length and quinolyl nitrogen pKa on activity vs chloroquine resistant malaria. J Med Chem (2008) 1.42
In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum. Antimicrob Agents Chemother (2008) 1.06
The antimalarial ferroquine: from bench to clinic. Parasite (2011) 0.93
The mechanism of antimalarial action of the ruthenium(II)-chloroquine complex [RuCl(2)(CQ)] (2). J Biol Inorg Chem (2008) 0.90
Metallocene antimalarials: the continuing quest. Met Based Drugs (2008) 0.77
Some nontoxic metal-based drugs for selected prevalent tropical pathogenic diseases. J Biol Inorg Chem (2016) 0.75
Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Am J Trop Med Hyg (2006) 2.34
Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Am J Trop Med Hyg (2006) 1.97
Antibody response against saliva antigens of Anopheles gambiae and Aedes aegypti in travellers in tropical Africa. Microbes Infect (2007) 1.63
Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malar J (2011) 1.63
Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine. Antimicrob Agents Chemother (2009) 1.59
Antimalarial drug susceptibility and point mutations associated with drug resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille, France in 2004 2006. Am J Trop Med Hyg (2007) 1.55
Motor-dependent microtubule disassembly driven by tubulin tyrosination. J Cell Biol (2009) 1.49
Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS One (2007) 1.44
Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. J Clin Microbiol (2010) 1.43
Multidrug resistance reversal agents. J Med Chem (2003) 1.42
Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malar J (2011) 1.40
Malaria transmission in Dakar: a two-year survey. Malar J (2008) 1.38
Physiological and retinoid-induced proliferations of epidermis basal keratinocytes are differently controlled. EMBO J (2002) 1.36
Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrob Agents Chemother (2007) 1.33
Multinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline. Antimicrob Agents Chemother (2008) 1.29
Genetic structure of Plasmodium falciparum and elimination of malaria, Comoros archipelago. Emerg Infect Dis (2010) 1.27
Pfhrp2 and pfhrp3 polymorphisms in Plasmodium falciparum isolates from Dakar, Senegal: impact on rapid malaria diagnostic tests. Malar J (2013) 1.23
Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother (2005) 1.23
Molecular surveillance of drug-resistant Plasmodium vivax using pvdhfr, pvdhps and pvmdr1 markers in Nouakchott, Mauritania. J Antimicrob Chemother (2011) 1.19
Selection of a trioxaquine as an antimalarial drug candidate. Proc Natl Acad Sci U S A (2008) 1.18
Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphisms and pftetQ and pfmdt copy numbers. J Infect Dis (2010) 1.18
In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooué region of Gabon. J Antimicrob Chemother (2003) 1.17
High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool. Antimicrob Agents Chemother (2013) 1.15
Antibody responses to several malaria pre-erythrocytic antigens as a marker of malaria exposure among travelers. Am J Trop Med Hyg (2006) 1.13
Artesunate tolerance in transgenic Plasmodium falciparum parasites overexpressing a tryptophan-rich protein. Antimicrob Agents Chemother (2011) 1.12
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. Antimicrob Agents Chemother (2009) 1.10
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob Agents Chemother (2010) 1.10
Malaria prevalence and morbidity among children reporting at health facilities in Nouakchott, Mauritania. Trans R Soc Trop Med Hyg (2011) 1.10
In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs. Antimicrob Agents Chemother (2011) 1.10
Antimalarial drug use in general populations of tropical Africa. Malar J (2008) 1.09
Chloroquine resistance reversal agents as promising antimalarial drugs. Curr Drug Targets (2006) 1.09
Triadin deletion induces impaired skeletal muscle function. J Biol Chem (2009) 1.09
The Toxoplasma gondii calcium-dependent protein kinase 7 is involved in early steps of parasite division and is crucial for parasite survival. Cell Microbiol (2013) 1.08
Synchrony of spontaneous calcium activity in mouse neocortex before synaptogenesis. Eur J Neurosci (2007) 1.08
In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Antimicrob Agents Chemother (2006) 1.08
Apicomplexan cytoskeleton and motors: key regulators in morphogenesis, cell division, transport and motility. Int J Parasitol (2008) 1.06
In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum. Antimicrob Agents Chemother (2008) 1.06
Malaria transmission and insecticide resistance of Anopheles gambiae in Libreville and Port-Gentil, Gabon. Malar J (2010) 1.06
Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure. Malar J (2006) 1.06
Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal. Malar J (2012) 1.06
Double staining of Plasmodium falciparum nucleic acids with hydroethidine and thiazole orange for cell cycle stage analysis by flow cytometry. Cytometry A (2004) 1.06
Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum. Malar J (2010) 1.05
Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol Pharm (2005) 1.04
Identification of a novel antigen of Schistosoma mansoni shared with Plasmodium falciparum and evaluation of different cross-reactive antibody subclasses induced by human schistosomiasis and malaria. Infect Immun (2006) 1.04
Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene. J Antimicrob Chemother (2010) 1.04
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA. J Med Chem (2010) 1.03
Influence of oxygen on asexual blood cycle and susceptibility of Plasmodium falciparum to chloroquine: requirement of a standardized in vitro assay. Malar J (2007) 1.02
Identification of a new member of the CD20/FcepsilonRIbeta family overexpressed in tolerated allografts. Am J Transplant (2005) 1.02
The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance. ACS Chem Biol (2011) 0.99
Determinants of compliance with malaria chemoprophylaxis among French soldiers during missions in inter-tropical Africa. Malar J (2010) 0.98
Ferroquine, an ingenious antimalarial drug: thoughts on the mechanism of action. Molecules (2008) 0.98
Use of the atmospheric generators for capnophilic bacteria Genbag-CO2 for the evaluation of in vitro Plasmodium falciparum susceptibility to standard anti-malarial drugs. Malar J (2011) 0.98
Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013-2014 malaria season. Malar J (2015) 0.97
Plasmodium falciparum proteome changes in response to doxycycline treatment. Malar J (2010) 0.96
Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study. Malar J (2013) 0.96
Efficacy of NZ2114, a novel plectasin-derived cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2011) 0.96
Malaria epidemic and drug resistance, Djibouti. Emerg Infect Dis (2005) 0.96
8-O-Azeloyl-14-benzoylaconine: a new alkaloid from the roots of Aconitum karacolicum Rapcs and its antiproliferative activities. Bioorg Med Chem (2005) 0.95
Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine. Malar J (2015) 0.95
Synthesis and preliminary in vitro evaluation of antimycobacterial activity of new pyrrolo[1,2-a] quinoxaline-carboxylic acid hydrazide derivatives. J Enzyme Inhib Med Chem (2004) 0.95
Salivary gland protein repertoire from Aedes aegypti mosquitoes. Vector Borne Zoonotic Dis (2010) 0.95
Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. Malar J (2012) 0.94
Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011. Malar J (2013) 0.93
Synthesis of new pyrrolo[1,2-a]quinoxaline derivatives as potential inhibitors of Akt kinase. J Enzyme Inhib Med Chem (2008) 0.93
Prenatal stress has pro-inflammatory consequences on the immune system in adult rats. Psychoneuroendocrinology (2007) 0.92
Innate refractoriness of the Lewis rat to toxoplasmosis is a dominant trait that is intrinsic to bone marrow-derived cells. Infect Immun (2005) 0.92
Synthesis of a novel class of non-peptide NK-2 receptor ligand, derived from 1-phenyl-3-pyrrol-1-ylindan-2-carboxamides. Bioorg Med Chem (2002) 0.92
Proveblue (methylene blue) as an antimalarial agent: in vitro synergy with dihydroartemisinin and atorvastatin. Antimicrob Agents Chemother (2012) 0.92
Dihydroethanoanthracene derivatives reverse in vitro quinoline resistance in Plasmodium falciparum malaria. Med Chem (2008) 0.92
Synthesis and in vitro activities of ferrocenic aminohydroxynaphthoquinones against Toxoplasma gondii and Plasmodium falciparum. Bioorg Med Chem (2005) 0.92
Marseilles: a surveillance site for malaria from the Comoros Islands. J Travel Med (2005) 0.92
Toxoplasma gondii myosin F, an essential motor for centrosomes positioning and apicoplast inheritance. EMBO J (2013) 0.92
Progressive cross-reactivity in IgE responses: an explanation for the slow development of human immunity to schistosomiasis? Infect Immun (2012) 0.92
Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model. Malar J (2013) 0.92
Inhibition of efflux of quinolines as new therapeutic strategy in malaria. Curr Top Med Chem (2008) 0.92
Differential association of Plasmodium falciparum Na+/H+ exchanger polymorphism and quinine responses in field- and culture-adapted isolates of Plasmodium falciparum. Antimicrob Agents Chemother (2011) 0.91
In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos (2006) 0.91
Multiple determinants in voltage-dependent P/Q calcium channels control their retention in the endoplasmic reticulum. Eur J Neurosci (2002) 0.91
Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin. Antimicrob Agents Chemother (2009) 0.90